A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Cetuximab; Trastuzumab; Trastuzumab emtansine
- Indications Solid tumours
- Focus Adverse reactions
- 24 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
- 24 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.